Hidden Vitamin Might Reverse Global Liver Crisis

Various herbal supplements and vitamins arranged with leaves and a mortar

A everyday vitamin hidden in your cupboard could reverse the silent liver epidemic striking one in three adults worldwide.

Story Snapshot

Niacin (vitamin B3) suppresses key genetic driver miR-93, slashing fat buildup, inflammation, and scarring in fatty liver disease.
Researchers screened 150 FDA-approved drugs; niacin topped the list for metabolic-associated steatohepatitis (MASLD).
First study links miR-93 to MASLD progression, validated in patients and gene-edited mice showing better insulin sensitivity.
Affects 30% globally; niacin’s low cost and safety profile promise quick trials and real-world access.

Researchers Uncover miR-93 as Fatty Liver Culprit

Professor Jang Hyun Choi at UNIST led a team from Pusan National University and Ulsan University Hospital. They analyzed liver samples from MASLD patients and mouse models. MicroRNA-93 (miR-93) emerged as the central driver. This tiny RNA molecule ramps up lipid accumulation, sparks inflammation, and triggers fibrosis. Overexpression worsened disease; knockout reversed it. Gene-edited mice confirmed miR-93’s role in insulin resistance and fat storage. Their work marks the first global map of this pathway in MASLD.

Niacin Suppresses miR-93 Through SIRT1 Activation

The team screened 150 FDA-approved drugs for miR-93 inhibitors. Niacin, or vitamin B3, proved most potent. It boosts SIRT1, a protein that restores lipid metabolism. In mouse models fed high-fat diets, niacin cut liver fat by enhancing fatty acid oxidation. Inflammation markers dropped; fibrosis eased. Patient liver biopsies mirrored these effects.

Timeline Traces Path from Discovery to Publication

Pre-2025 research highlighted MASLD’s treatment void amid obesity surges since the 1980s. In 2025, Choi’s collaboration pinpointed miR-93. They validated it across human and animal data. Drug screening crowned niacin. On September 12, 2025, results hit Metabolism: Clinical and Experimental online. This timeline underscores rapid translation from bench to potential bedside, funded by Korea’s National Research Foundation.

Lean NAFLD and Vitamin D Add Complementary Insights

Gang Ma’s team at Xijing Hospital analyzed NHANES data from 4,201 adults. They found an L-shaped link between vitamin D levels and lean NAFLD (BMI under 25). Risk spiked below 60.3 nmol/L, then plateaued. Nonlinear models beat linear ones, revealing hidden patterns. Early 2026 epub confirmed this. Such findings spotlight non-obese cases, urging targeted screening.

UConn Patent Targets lncRNA for Disease Reversal

Dr. Shi-Chao Zhong at UConn filed a March 3, 2026, provisional patent for HNF4A-AS1 inhibitors. These ASOs and siRNAs hit upstream genetic regulators in MASLD and MASH. Zhong predicts pharma disruption by enabling full reversal, not just symptom control. NIH-funded, this builds on niacin’s momentum. Preclinical stages dominate; human trials loom. Patent dynamics favor innovators tackling root causes with proven safety.

• #Science #Physics #Chemistry #BioScience #Mathematics #Quantum #Nuclear #Engineering 🧬 •

» Fatty liver breakthrough: A common vitamin shows promise https://t.co/yK1QLP6F2j

— Tathagata M. (@tatha_gautama) March 25, 2026

Implications Reshape Treatment and Access

Short-term, niacin eyes clinical trials; vitamin D checks below 60 nmol/L flag lean risks. Long-term, genetic targeting via miR-93 or HNF4A-AS1 shifts from lifestyle bandaids to cures. Impacts 30% worldwide, easing economic burdens with cheap niacin. Repurposed vitamins democratize care, challenging big pharma’s metabolic drug monopoly while prioritizing patient outcomes.